Piperaquine + pyronaridine

Product development

-

Patient exploratory

Shin Poong

Causal prophylaxis

Intermittent preventative treatment (TPP-1)

Chemoprophylaxis (TPP-2)

Product vision	Malaria chemoprevention in pregnant women and children
MOA	Piperaquine: unknown MoA, but likely mirrors that of chloroquine, which binds to toxic haem within the malaria parasite, preventing its detoxification via a polymerisation step Pyronaridine: pleotropic effect including inhibition of hematin formation, and haem degradation. Interferes with the digestive system of the parasite by modifying food vacuoles
Key features	High tolerability, good safety profile, anticipated comparatively long duration of protection & low risk of emergence of resistance, no teratogenic liabilities
Challenges	Demonstration of increased bioavailability and minimal impact of food on pharmacokinetic exposure of dispersible piperaquine granule formulation Demonstration of safety/tolerability and efficacy of single dose monthly administration, in preventing and clearing malaria infections
Status	Combination safety phase I study in healthy volunteers completed
Next milestone	Dispersible piperaquine granule formulation relative bioavailability and food effect in healthy volunteers study start Initiate phase II to characterize the safety/tolerability and efficacy of single dose monthly administration in healthy and asymptomatic non-pregnant women
Project Director	Dr Isabelle Borghini Fuhrer